Illumina's Q2 Array Sales Rise 3 Percent on Demand for Infinium, BlueGnome Chips, Consumer Genetics | GenomeWeb

Illumina's microarray business continued to grow in the second quarter, with customer demand for its Omni and Core families of genotyping arrays, contributions from recent addition BlueGnome, and sales to direct-to-consumer genetics firms such as 23andMe and Ancestry.com pushing Q2 array revenues up 3 percent year over year.

CEO Jay Flatley told investors in an earnings call that demand for arrays remains "stable" as the market trends toward using arrays to genotype "large sample numbers with moderate content at a lower [average selling price] per sample."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.